Sandramycin (CAS 100940-65-6)

Sandramycin, a member of the anthracycline family of antibiotics, has attracted considerable interest in scientific research due to its potent anticancer properties and distinctive mechanism of action. This compound exerts its cytotoxic effects by intercalating into DNA strands and inhibiting topoisomerase II, a critical enzyme involved in DNA replication and repair processes. By interfering with topoisomerase II-mediated DNA cleavage and religation, sandramycin induces double-strand DNA breaks and prevents DNA synthesis, ultimately leading to cell cycle arrest and apoptosis in cancer cells. Research has further explaind the structural features of sandramycin and its binding interactions with DNA and topoisomerase II, providing insights into its mechanism of action and potential for the development of novel anticancer agents. Additionally, sandramycin has been investigated in combination therapy regimens with other anticancer agents, aiming to enhance its efficacy and minimize adverse effects. Furthermore, studies have explored the potential of sandramycin analogs and derivatives as scaffolds for the development of new anticancer drugs with improved pharmacological properties and reduced toxicity. Overall, sandramycin represents a valuable tool in cancer research, offering insights into DNA-targeted anticancer strategies and serving as a potential lead compound for cancer research.